Global Single-Photon Emission Computed Tomography (SPECT) Market Size By Product (Standalone SPECT, Hybrid SPECT), By Application (Cardiology, Oncology), By ENd-User (Hospitals, Diagnostic Imaging Centers), By Geographic Scope And Forecast
Published on: 2024-08-04 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Global Single-Photon Emission Computed Tomography (SPECT) Market Size By Product (Standalone SPECT, Hybrid SPECT), By Application (Cardiology, Oncology), By ENd-User (Hospitals, Diagnostic Imaging Centers), By Geographic Scope And Forecast
Single-Photon Emission Computed Tomography (SPECT) Market Size And Forecast
Single-Photon Emission Computed Tomography (SPECT) Market size was valued at USD 1.88 Billion in 2024 and is projected to reach USD 3.15 Billion by 2031, growing at a CAGR of 6.70% from 2024 to 2031.
The Single-Photon Emission Computed Tomography (SPECT) Market is expanding as a result of developments in SPECT technology as well as the rising incidence of cardiac and cancer disorders worldwide. Furthermore, increased investment in modern diagnostic facilities and rising knowledge among people regarding diagnosis are supporting the growth of the SPECT Industry. The Global Single-Photon Emission Computed Tomography (SPECT) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Single-Photon Emission Computed Tomography (SPECT) Market Definition
An imaging examination called a single photon emission computed tomography (SPECT) reveals how blood flows to various organs and tissues. It is utilized to identify cardiovascular problems, cancer, and neurological conditions as well as strokes, seizures, stress fractures, infections, and spinal tumours. A radioactive tracer and computed tomography (CT) are used in a nuclear imaging scan to provide a diagnosis. The radiolabeled tracer allows medical professionals to examine how blood flows to tissues and organs by emitting gamma rays that the CT scanner can detect. Computers gather data from the gamma-ray emissions, which are then shown on the CT cross-sections. The brain and other organs are shown in three dimensions using these cross-sections.
In the SPECT, radioisotopes including technetium-99m, thallium-201, odine-123, fluorine-18, and xenon-133 are used. Blood flow via arteries and veins in the brain and spine can be detected with a SPECT scan. Studies have demonstrated that because it is utilized to identify decreased blood flow to affected regions, it may provide more accurate findings for brain injury than MRI or CT scanning. The blood flow through the heart is examined using cardiac SPECT scans; regions of the heart with inadequate blood flow will look dark, while parts with normal blood flow will appear bright. Furthermore, it is used to diagnose undetected bone fractures, such as stress fractures and shin splints.
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Global Single-Photon Emission Computed Tomography (SPECT) Market Overview
The market is growing because of the increase in individuals suffering from malignancies, cardiovascular diseases, and other critical ailments. The market is primarily driven by the quickly growing healthcare industry. The market is expected to expand because of ageing populations and the prevalence of ailments brought on by a sedentary lifestyle. The development of SPECT equipment’s diagnostic capabilities has also been considerably aided by the rising usage of dual-modality and organ-specific systems throughout time. Another element driving market expansion is the rise in coronary artery diseases. The need for hybrid SPECT imaging systems is currently increasing. Two other factors that encourage expansion are expanding research into the production of radiopharmaceuticals and increasing public knowledge of the multiple benefits that the testing type has over other imaging techniques. The development of new radiotracers and ongoing technological improvements in system design further boost market expansion. Gallium-67 is the gold standard for tumour diagnosis and staging. Using Ga-67 SPECT/CT in hybrid imaging, lymphoma lesions may be accurately identified.
Ga-67 is a commonly used agent for the imaging of inflammation because of its ability to concentrate not specifically in inflamed tissues as a metal-transferrin complex, followed by further binding to transferrin receptors. A number of market participants, including Lantheus Medical Imaging and Mallinckrodt Nuclear, provides gallium citrate GA-67. Consequently, it is projected that the market would expand rapidly during the forecast period and present business possibilities as a result of the rising frequency of different cancers and bone conditions as well as the benefits of gallium-67. Molecular isotopes are required for diagnostic imaging equipment, however, throughout the anticipated period, a shortage of supply and insufficient availability of these isotopes is predicted to restrain the expansion of the global SPECT market. As an example, there have been multiple supply shortages for the two chemical elements technetium and molybdenum during the past few years, which are often utilized in a significant number of SPECT procedures in cardiology.
An additional factor that has had an impact on the supply of molecular isotopes is the fact that the reactors that provided the isotopes were indefinitely shut down in some regions owing to safety-related concerns. Recalls of products are another factor that is hurting the global market for SPECT. The application of SPECT equipment for lesions, illnesses, and organ dysfunctions, such as cardiovascular disease, cancer, and brain dysfunction, has adverse effects on restaging, diagnosis, staging, and follow-up. The global market for SPECT devices is having problems increasing its revenue because of product recalls and the negative impacts of SPECT devices.
Global Single-Photon Emission Computed Tomography (SPECT) Market Segmentation Analysis
The Global Single-Photon Emission Computed Tomography (SPECT) Market is segmented on the basis of Product, Application, End-User, And Geography.
Single-Photon Emission Computed Tomography (SPECT) Market, By Product
- Standalone SPECT
- Hybrid SPECT
Based on Product, the market is bifurcated into Standalone SPECT and Hybrid SPECT. The Standalone SPECT technology segment accounted for the largest market share in 2022 and is projected to grow at a significant CAGR during the forecast period. The segment’s expansion is driven by cancer and heart divisions’ increasing use of Standalone SPECT. Gamma ray-based nuclear medicine imaging systems are a type of standalone SPECT. The device can produce high-quality full-body tomographic pictures in real time and detects the gamma-ray emissions from an injected radioisotope to provide images for diagnosis and illness management.
Single-Photon Emission Computed Tomography (SPECT) Market, By Application
- Cardiology
- Oncology
- General Imaging
- Neurology
- Other
Based on Application, the market is bifurcated into Cardiology, Oncology, General Imaging, Neurology, and Other. The segment cardiology accounted for the largest market share in 2022 and is projected to grow at the highest CAGR during the forecast period. Cardiologists use SPECT to see the different parts of the heart’s blood flow. By administering a radioactive tracer that has been tagged with gamma cameras, doctors can examine where and how well blood flows into and around the heart. These let doctors determine whether conditions like atherosclerosis, coronary artery disease, hypertension, valvular illnesses like mitral valve prolapse, congenital bicuspid valves caused by an infection in early childhood, etc. have negatively impacted a patient’s heart. The segment is expanding as a result of the globalization of cardiovascular diseases as well as increased public knowledge of heart disease diagnostics.
Single-Photon Emission Computed Tomography (SPECT) Market, By End-User
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
Based on End-User, the market is segmented into hospitals, diagnostic imaging centers, and ambulatory surgical centers. Hospitals segment accounted for the largest market share in 2022 and is projected to grow at the highest CAGR during the forecast period. The market is expected to expand as a result of ageing populations and the prevalence of ailments brought on by a sedentary lifestyle. The development of SPECT equipment’s diagnostic capabilities has also been considerably aided by the rising usage of dual-modality and organ-specific systems throughout time.
Single-Photon Emission Computed Tomography (SPECT) Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the world
Based on regional analysis, the Global Single-Photon Emission Computed Tomography (SPECT) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share and is projected to grow at a significant CAGR during the forecast period. The region’s big ageing population, high prevalence of cancer cases, and high number of cardiac patients are all driving the growth of the SPECT market there.
Key Players
The “Global Single-Photon Emission Computed Tomography (SPECT) Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Siemens Healthineers, Bruker, Toshiba Medical (Canon), Digirad Corporation, Esaote, Invicro, GE Healthcare, Philips Healthcare, LambdaSpect, Mediso Medical Imaging Systems, MR Solutions, TriFoil Imaging, among others. This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.
Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.
Key Developments
- In March 2022, Two radiopharmaceuticals in development by GE Healthcare are one for Positron Emission Tomography (PET) and the other is for Single-Photon Release Calculated Tomography imaging. A PET radiopharmaceutical imaging intermediary that intends to help in the assessment of adult patients with purported Parkinsonian disorders, provide research, and enhance patient maintenance was recently announced by the business as having its first patient treated in Phase III clinical study.
- In June 2021, Noria Therapeutics Inc. and PSMA Therapeutics Inc. have entered into a contract with Bayer to be acquired. Through this deal, Bayer will acquire the sole rights to a small molecule targeted at prostate-specific membrane antigen (PSMA) and a differentiated alpha radionuclide investigational drug based on actinium-225.
- In March 2021, IBA (Ion Beam Applications SA and EURONEXT) and NorthStar Medical Radioisotopes LLC declared a partnership to expand technetium-99m (Tc-99m) availability on a worldwide scale. By working together, NorthStar and IBA may develop non-uranium-based Mo-99 for their proprietary Tc-99m Generation Systems (TCM Generation Systems), which are available to businesses outside of the US.
- In November 2020, Prismatic Sensors AB, a Swedish start-up specialising on photon including detectors, was acquired by GE Healthcare, indicating the company’s sustained strength in photon counting CT technology. The scientific performance for cancer, cardiology, neurology, and many other clinical CT claims may be greatly improved with this understanding.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Single-Photon Emission Computed Tomography (SPECT) Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.